Phosphodiesterase Inhibitors
- 1st Edition - August 27, 1996
- Latest edition
- Editors: Christian Schudt, Clive Page, Gordon Dent, Klaus F. Rabe
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 2 1 0 7 2 0 - 7
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 5 3 8 8 1 - 5
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE… Read more
Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting.
- Utilizes actual testing and research of new PDE inhibitors
- Valuable for researchers and students alike
Research level pharmacologists, immunologists, and cell biologists; as a reference text in this area for those involved in degree-level teaching. Pharmaceutical companies.
K.M. Ferguson and K. Loughney, Identification and Quantification of PDE Isoenzymes and Subtypes by Molecular Biological Methods.
H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods.
K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function.
R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions.
R. Fischmeister, EHNA as an Inhibitor of PDE II.
V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents.
M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential.
P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors.
J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I.
A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors.
R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344.
J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401.
T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV.
Subject Index.
H. Tenor and C. Schudt, Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods.
K.F. Rabe, Effects of Theophylline and Nonselective Xanthine Derivatives on PDE Isoenzymes and Cellular Function.
R.K. Sharma, Interaction of PDE I Inhibitors with Isoenzymes and Cell Functions.
R. Fischmeister, EHNA as an Inhibitor of PDE II.
V.C. Manganiello, PDE II Inhibitors as Therapeutic Agents.
M.A. Giembycz, Interaction of PDE IV Inhibitors with Enzymes and Cell Functions and their Therapeutic Potential.
P.J. Silver, Inhibition of PDE Isoenzymes and Cell Function by Selective PDE V Inhibitors.
J.D. Corbin, Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE V and PDE I.
A. Hatzelmann, Enzymatic and Functional Inhibition of Dual-Selective Inhibitors.
R. Alvarez, Subtype Selectivity, Inhibition of Cell Function and Therapeutic Potential of RS 25344.
J.E. Souness, Characterization of Different States of PDE IV by Rolipram and RP 73401.
T.J. Torphy, Functional Significance of Two Sites for Inhibitors at PDE IV.
Subject Index.
- Edition: 1
- Latest edition
- Published: August 27, 1996
- Language: English
CS
Christian Schudt
Affiliations and expertise
Byk Gulden Pharmaceuticals, Konstan, GermanyCP
Clive Page
Professor Clive P. Page, BSc PhD OBE HonFBPhS is a Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Non Executive Director of and on boards of several companies. He was awarded the Society of Biology President’s Medal in 2012 for an outstanding contribution to the life sciences over the previous year. He is a Fellow of the Royal Society of Biology and an Honorary Fellow and President Elect of the British Pharmacological Society. In 2017, Clive was awarded an OBE for Services to Pharmacology.
Affiliations and expertise
Professor of Pharmacology, King’s College London and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London, UK
GD
Gordon Dent
Affiliations and expertise
Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, GermanyKR
Klaus F. Rabe
Affiliations and expertise
Kraankenhaus Grobhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, GermanyRead Phosphodiesterase Inhibitors on ScienceDirect